Next 10 |
2024-04-18 05:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-17 14:00:04 ET Mohit Bansal from Wells Fargo issued a price target of $320.00 for AMGN on 2024-04-17 12:30:00. The adjusted price target was set to $320.00. At the time of the announcement, AMGN was trading at $265.105. The overall price target consensus is at $2...
2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...
2024-04-17 07:30:00 ET Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500 's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds. Amgen (NASDAQ: AMGN) , a top-tier U.S. biotech fir...
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 PR Newswire Planning Underway for Phase 3 Development of Tezepelumab in COPD THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the r...
2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...
2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...
2024-04-15 08:15:00 ET Summary Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry. AMGN is executing well with sales and volume growth, and has a robust development pipeline. Biosimilars growth is ac...
2024-04-15 04:25:44 ET Summary Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024, focusing on expanding sales of rare disease drugs and ...
2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...
News, Short Squeeze, Breakout and More Instantly...
2024-04-18 05:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in...
2024-04-17 14:00:04 ET Mohit Bansal from Wells Fargo issued a price target of $320.00 for AMGN on 2024-04-17 12:30:00. The adjusted price target was set to $320.00. At the time of the announcement, AMGN was trading at $265.105. The overall price target consensus is at $2...